| Year |
Citation |
Score |
| 2024 |
Kasikova L, Rakova J, Hensler M, Lanickova T, Tomankova J, Pasulka J, Drozenova J, Mojzisova K, Fialova A, Vosahlikova S, Laco J, Ryska A, Dundr P, Kocian R, Brtnicky T, ... ... Orsulic S, et al. Tertiary lymphoid structures and B cells determine clinically relevant T cell phenotypes in ovarian cancer. Nature Communications. 15: 2528. PMID 38514660 DOI: 10.1038/s41467-024-46873-w |
0.301 |
|
| 2024 |
Broz MT, Ko EY, Ishaya K, Xiao J, De Simone M, Hoi XP, Piras R, Gala B, Tessaro FHG, Karlstaedt A, Orsulic S, Lund AW, Chan KS, Guarnerio J. Metabolic targeting of cancer associated fibroblasts overcomes T-cell exclusion and chemoresistance in soft-tissue sarcomas. Nature Communications. 15: 2498. PMID 38509063 DOI: 10.1038/s41467-024-46504-4 |
0.376 |
|
| 2024 |
Hu Y, Recouvreux MS, Haro M, Taylan E, Taylor-Harding B, Walts AE, Karlan BY, Orsulic S. INHBA(+) cancer-associated fibroblasts generate an immunosuppressive tumor microenvironment in ovarian cancer. Npj Precision Oncology. 8: 35. PMID 38360876 DOI: 10.1038/s41698-024-00523-y |
0.557 |
|
| 2023 |
Saner FAM, Takahashi K, Budden T, Pandey A, Ariyaratne D, Zwimpfer TA, Meagher NS, Fereday S, Twomey L, Pishas KI, Hoang T, Bolithon A, Traficante N, Alsop K, Christie EL, ... ... Orsulic S, et al. Concurrent RB1 loss and -deficiency predicts enhanced immunological response and long-term survival in tubo-ovarian high-grade serous carcinoma. Medrxiv : the Preprint Server For Health Sciences. PMID 37986741 DOI: 10.1101/2023.11.09.23298321 |
0.311 |
|
| 2023 |
Zhang Y, Wang Y, Zhao G, Orsulic S, Matei D. Metabolic dependencies and targets in ovarian cancer. Pharmacology & Therapeutics. 245: 108413. PMID 37059310 DOI: 10.1016/j.pharmthera.2023.108413 |
0.488 |
|
| 2022 |
Kang EY, Weir A, Meagher NS, Farrington K, Nelson GS, Ghatage P, Lee CH, Riggan MJ, Bolithon A, Popovic G, Leung B, Tang K, Lambie N, Millstein J, Alsop J, ... ... Orsulic S, et al. CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study. Cancer. PMID 36572991 DOI: 10.1002/cncr.34582 |
0.302 |
|
| 2022 |
Richardson MT, Recouvreux MS, Karlan BY, Walts AE, Orsulic S. Ciliated Cells in Ovarian Cancer Decrease with Increasing Tumor Grade and Disease Progression. Cells. 11. PMID 36552773 DOI: 10.3390/cells11244009 |
0.418 |
|
| 2022 |
Gertych A, Walts AE, Cheng K, Liu M, John J, Lester J, Karlan BY, Orsulic S. Dynamic Changes in the Extracellular Matrix in Primary, Metastatic, and Recurrent Ovarian Cancers. Cells. 11. PMID 36497028 DOI: 10.3390/cells11233769 |
0.466 |
|
| 2022 |
Recouvreux MS, Miao J, Gozo MC, Wu J, Walts AE, Karlan BY, Orsulic S. FOXC2 Promotes Vasculogenic Mimicry in Ovarian Cancer. Cancers. 14. PMID 36230774 DOI: 10.3390/cancers14194851 |
0.552 |
|
| 2022 |
Meagher NS, Gorringe KL, Wakefield MJ, Bolithon A, Pang CNI, Chiu DS, Anglesio MS, Mallitt KA, Doherty JA, Harris HR, Schildkraut JM, Berchuck A, Cushing-Haugen KL, Chezar K, Chou A, ... ... Orsulic S, et al. Gene expression profiling of mucinous ovarian tumors and comparison with upper and lower gastrointestinal tumors identifies markers associated with adverse outcomes. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 36222710 DOI: 10.1158/1078-0432.CCR-22-1206 |
0.346 |
|
| 2022 |
Zhao G, Tan Y, Cardenas H, Vayngart D, Wang Y, Huang H, Keathley R, Wei JJ, Ferreira CR, Orsulic S, Cheng JX, Matei D. Ovarian cancer cell fate regulation by the dynamics between saturated and unsaturated fatty acids. Proceedings of the National Academy of Sciences of the United States of America. 119: e2203480119. PMID 36197994 DOI: 10.1073/pnas.2203480119 |
0.378 |
|
| 2022 |
Orsulic S, John J, Walts AE, Gertych A. Computational pathology in ovarian cancer. Frontiers in Oncology. 12: 924945. PMID 35965569 DOI: 10.3389/fonc.2022.924945 |
0.404 |
|
| 2021 |
Yucer N, Ahdoot R, Workman MJ, Laperle AH, Recouvreux MS, Kurowski K, Naboulsi DJ, Liang V, Qu Y, Plummer JT, Gayther SA, Orsulic S, Karlan BY, Svendsen CN. Human iPSC-derived fallopian tube organoids with BRCA1 mutation recapitulate early-stage carcinogenesis. Cell Reports. 37: 110146. PMID 34965417 DOI: 10.1016/j.celrep.2021.110146 |
0.437 |
|
| 2021 |
Dinh HQ, Pan F, Wang G, Huang QF, Olingy CE, Wu ZY, Wang SH, Xu X, Xu XE, He JZ, Yang Q, Orsulic S, Haro M, Li LY, Huang GW, et al. Integrated single-cell transcriptome analysis reveals heterogeneity of esophageal squamous cell carcinoma microenvironment. Nature Communications. 12: 7335. PMID 34921160 DOI: 10.1038/s41467-021-27599-5 |
0.433 |
|
| 2021 |
Fucikova J, Coosemans A, Orsulic S, Cibula D, Vergote I, Galluzzi L, Spisek R. Immunological configuration of ovarian carcinoma: features and impact on disease outcome. Journal For Immunotherapy of Cancer. 9. PMID 34645669 DOI: 10.1136/jitc-2021-002873 |
0.319 |
|
| 2020 |
Glubb DM, Thompson DJ, Aben KK, Alsulimani A, Amant F, Annibali D, Attia J, Barricarte A, Beckmann MW, Berchuck A, Bermisheva M, Bernardini MQ, Bischof K, Bjørge L, Bodelon C, ... ... Orsulic S, et al. Cross-cancer genome-wide association study of endometrial cancer and epithelial ovarian cancer identifies genetic risk regions associated with risk of both cancers. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 33144283 DOI: 10.1158/1055-9965.EPI-20-0739 |
0.458 |
|
| 2020 |
Hu Y, Taylor-Harding B, Raz Y, Haro M, Recouvreux MS, Taylan E, Lester J, Millstein J, Walts AE, Karlan BY, Orsulic S. Are Epithelial Ovarian Cancers of the Mesenchymal Subtype Actually Intraperitoneal Metastases to the Ovary? Frontiers in Cell and Developmental Biology. 8: 647. PMID 32766252 DOI: 10.3389/Fcell.2020.00647 |
0.55 |
|
| 2020 |
Taylan E, Zayou F, Murali R, Karlan BY, Pandol SJ, Edderkaoui M, Orsulic S. Dual targeting of GSK3B and HDACs reduces tumor growth and improves survival in an ovarian cancer mouse model. Gynecologic Oncology. PMID 32698955 DOI: 10.1016/J.Ygyno.2020.07.005 |
0.542 |
|
| 2020 |
Martins FC, Couturier DL, Paterson A, Karnezis AN, Chow C, Nazeran TM, Odunsi A, Gentry-Maharaj A, Vrvilo A, Hein A, Talhouk A, Osorio A, Hartkopf AD, Brooks-Wilson A, DeFazio A, ... ... Orsulic S, et al. Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium. British Journal of Cancer. PMID 32555365 DOI: 10.1038/S41416-020-0900-0 |
0.576 |
|
| 2020 |
Talhouk A, George J, Wang C, Budden T, Tan TZ, Chiu DS, Kommoss S, Leong HS, Chen S, Intermaggio MP, Gilks B, Nazeran TM, Volchek M, Elatre W, Bentley RC, ... ... Orsulic S, et al. Development and validation of the gene-expression Predictor of high-grade-serous Ovarian carcinoma molecular subTYPE (PrOTYPE). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32554541 DOI: 10.1158/1078-0432.Ccr-20-0103 |
0.447 |
|
| 2020 |
Millstein J, Budden T, Goode EL, Anglesio MS, Talhouk A, Intermaggio MP, Leong HS, Chen S, Elatre W, Gilks B, Nazeran T, Volchek M, Bentley RC, Wang C, Chiu DS, ... ... Orsulic S, et al. Prognostic gene expression signature for high-grade serous ovarian cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 32473302 DOI: 10.1016/J.Annonc.2020.05.019 |
0.473 |
|
| 2020 |
Lahiguera Á, Hyroššová P, Figueras A, Garzón D, Moreno R, Soto-Cerrato V, McNeish I, Serra V, Lazaro C, Barretina P, Brunet J, Menéndez J, Matias-Guiu X, Vidal A, Villanueva A, ... ... Orsulic S, et al. Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with PARP inhibitors. Embo Molecular Medicine. e11217. PMID 32400970 DOI: 10.15252/Emmm.201911217 |
0.486 |
|
| 2020 |
Aspuria PJ, Cheon DJ, Gozo MC, Beach JA, Recouvreux MS, Walts AE, Karlan BY, Orsulic S. HOXB13 controls cell state through super-enhancers. Experimental Cell Research. 112039. PMID 32376288 DOI: 10.1016/J.Yexcr.2020.112039 |
0.429 |
|
| 2020 |
Nallanthighal S, Rada M, Heiserman JP, Cha J, Sage J, Zhou B, Yang W, Hu Y, Korgaonkar C, Hanos CT, Ashkavand Z, Norman K, Orsulic S, Cheon DJ. Inhibition of collagen XI alpha 1-induced fatty acid oxidation triggers apoptotic cell death in cisplatin-resistant ovarian cancer. Cell Death & Disease. 11: 258. PMID 32312965 DOI: 10.1038/S41419-020-2442-Z |
0.509 |
|
| 2019 |
Orsulic S, Karlan BY. Can molecular subtyping be used to triage women with advanced ovarian cancer to Primary Debulking Surgery or Neoadjuvant Chemotherapy? Gynecologic Oncology. 152: 221-222. PMID 30704616 DOI: 10.1016/J.Ygyno.2019.01.005 |
0.435 |
|
| 2018 |
Haro M, Orsulic S. A Paradoxical Correlation of Cancer-Associated Fibroblasts With Survival Outcomes in B-Cell Lymphomas and Carcinomas. Frontiers in Cell and Developmental Biology. 6: 98. PMID 30211161 DOI: 10.3389/Fcell.2018.00098 |
0.552 |
|
| 2018 |
Kelemen LE, Earp M, Fridley BL, Chenevix-Trench G, Fasching PA, Beckmann MW, Ekici AB, Hein A, Lambrechts D, Lambrechts S, Van Nieuwenhuysen E, Vergote I, Rossing MA, Doherty JA, ... ... Orsulic S, et al. rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. International Journal of Molecular Sciences. 19. PMID 30134598 DOI: 10.3390/Ijms19092473 |
0.35 |
|
| 2018 |
Jia D, Nagaoka Y, Katsumata M, Orsulic S. Inflammation is a key contributor to ovarian cancer cell seeding. Scientific Reports. 8: 12394. PMID 30120290 DOI: 10.1038/S41598-018-30261-8 |
0.788 |
|
| 2018 |
Earp M, Tyrer JP, Winham SJ, Lin HY, Chornokur G, Dennis J, Aben KKH, Anton-Culver H, Antonenkova N, Bandera EV, Bean YT, Beckmann MW, Bjorge L, Bogdanova N, Brinton LA, ... ... Orsulic S, et al. Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. Plos One. 13: e0197561. PMID 29979793 DOI: 10.1371/Journal.Pone.0197561 |
0.415 |
|
| 2018 |
Rada M, Nallanthighal S, Cha J, Ryan K, Sage J, Eldred C, Ullo M, Orsulic S, Cheon DJ. Inhibitor of apoptosis proteins (IAPs) mediate collagen type XI alpha 1-driven cisplatin resistance in ovarian cancer. Oncogene. PMID 29769618 DOI: 10.1038/S41388-018-0297-X |
0.596 |
|
| 2018 |
Berger AC, Korkut A, Kanchi RS, Hegde AM, Lenoir W, Liu W, Liu Y, Fan H, Shen H, Ravikumar V, Rao A, Schultz A, Li X, Sumazin P, Williams C, ... ... Orsulic S, et al. A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers. Cancer Cell. PMID 29622464 DOI: 10.1016/J.Ccell.2018.03.014 |
0.471 |
|
| 2018 |
Dixon-Suen SC, Nagle CM, Thrift AP, Pharoah PDP, Ewing A, Pearce CL, Zheng W, Chenevix-Trench G, Fasching PA, Beckmann MW, Lambrechts D, Vergote I, Lambrechts S, Van Nieuwenhuysen E, ... ... Orsulic S, et al. Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. British Journal of Cancer. PMID 29555990 DOI: 10.1038/S41416-018-0011-3 |
0.464 |
|
| 2018 |
Block MS, Vierkant RA, Rambau PF, Winham SJ, Wagner P, Traficante N, Tołoczko A, Tiezzi DG, Taran FA, Sinn P, Sieh W, Sharma R, Rothstein JH, Ramón Y Cajal T, Paz-Ares L, ... ... Orsulic S, et al. MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. Mayo Clinic Proceedings. 93: 307-320. PMID 29502561 DOI: 10.1016/j.mayocp.2017.10.023 |
0.398 |
|
| 2018 |
Millstein J, Budden T, Anglesio M, Talhouk A, Beeghly-Fadiel A, Berchuck A, Chenevix-Trench G, deFazio A, Fasching PA, Gayther S, García M, Goode EL, Henderson M, Konecny GE, Orsulic S, et al. A gene expression prognostic signature for overall survival in patients with high-grade serous ovarian cancer. Journal of Clinical Oncology. 36: 5583-5583. DOI: 10.1200/Jco.2018.36.15_Suppl.5583 |
0.492 |
|
| 2018 |
Rodriguez-Malave NI, Kanska JE, Vavra KC, Hazelett D, Corona RI, Seo J, Freedman M, Knott SR, Orsulic S, Karlan BY, Lawrenson K, Gayther SA. Abstract 5435: Role of the WT1 transcription factor in high-grade serous ovarian cancer Cancer Research. 78: 5435-5435. DOI: 10.1158/1538-7445.Am2018-5435 |
0.56 |
|
| 2017 |
Goode EL, Block MS, Kalli KR, Vierkant RA, Chen W, Fogarty ZC, Gentry-Maharaj A, Toloczko A, Hein A, Bouligny AL, Jensen A, Osorio A, Hartkopf AD, Ryan A, ... ... Orsulic S, et al. Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. Jama Oncology. e173290. PMID 29049607 DOI: 10.1001/Jamaoncol.2017.3290 |
0.447 |
|
| 2017 |
Kanska J, Aspuria PP, Taylor-Harding B, Spurka L, Funari V, Orsulic S, Karlan BY, Wiedemeyer WR. Glucose deprivation elicits phenotypic plasticity via ZEB1-mediated expression of NNMT. Oncotarget. PMID 28412735 DOI: 10.18632/Oncotarget.15429 |
0.431 |
|
| 2017 |
Orsulic S. Response to the Letter to the Editor on: "A COL11A1-correlated pan-cancer gene signature of activated fibroblasts for the prioritization of therapeutic targets," Cancer Lett. 2016 Nov 28;382(2):203-214. Cancer Letters. 393: 127-128. PMID 28189535 DOI: 10.1016/J.Canlet.2017.02.001 |
0.534 |
|
| 2017 |
Rada M, Eldred C, Sage J, Orsulic S, Cheon D. Abstract TMEM-017: COLLAGEN TYPE XI ALPHA 1 (COL11A1) IS A NOVEL STROMAL MEDIATOR OF CHEMORESISTANCE Clinical Cancer Research. 23. DOI: 10.1158/1557-3265.Ovcasymp16-Tmem-017 |
0.857 |
|
| 2017 |
Robillard L, Nguyen M, Loehr A, Orsulic S, Kristeleit RS, Lin K, Raponi M, Harding TC, Simmons AD. Abstract 3650: Preclinical evaluation of the PARP inhibitor rucaparib in combination with PD-1 and PD-L1 inhibition in a syngeneic BRCA1 mutant ovarian cancer model Cancer Research. 77: 3650-3650. DOI: 10.1158/1538-7445.Am2017-3650 |
0.343 |
|
| 2017 |
Rada M, Cha J, Sage J, Orsulic S, Cheon D. Abstract 2975: Collagen type XI alpha 1 confers cisplatin chemoresistance in ovarian cancer through inhibitor of apoptosis proteins (IAPs) Cancer Research. 77: 2975-2975. DOI: 10.1158/1538-7445.Am2017-2975 |
0.838 |
|
| 2016 |
Sucheston-Campbell LE, Cannioto R, Clay AI, Etter JL, Eng KH, Liu S, Battaglia S, Hu Q, Szender JB, Minlikeeva A, Joseph J, Mayor P, Abrams SI, Segal B, Wallace PK, ... ... Orsulic S, et al. No evidence that genetic variation in the myeloid-derived suppressor cell pathway influences ovarian cancer survival. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 27677730 DOI: 10.1158/1055-9965.Epi-16-0631 |
0.559 |
|
| 2016 |
Gozo MC, Jia D, Aspuria PJ, Cheon DJ, Miura N, Walts AE, Karlan BY, Orsulic S. FOXC2 augments tumor propagation and metastasis in osteosarcoma. Oncotarget. PMID 27634875 DOI: 10.18632/Oncotarget.11990 |
0.752 |
|
| 2016 |
Jia D, Liu Z, Deng N, Tan TZ, Huang RY, Taylor-Harding B, Cheon DJ, Lawrenson K, Wiedemeyer WR, Walts AE, Karlan BY, Orsulic S. A COL11A1-correlated pan-cancer gene signature of activated fibroblasts for the prioritization of therapeutic targets. Cancer Letters. PMID 27609069 DOI: 10.1016/J.Canlet.2016.09.001 |
0.789 |
|
| 2016 |
French JD, Johnatty SE, Lu Y, Beesley J, Gao B, Kalimutho M, Henderson MJ, Russell AJ, Kar S, Chen X, Hillman KM, Kaufmann S, Sivakumaran H, O'Reilly M, Wang C, ... ... Orsulic S, et al. Germline polymorphisms in an enhancer of PSIP1 are associated with progression-free survival in epithelial ovarian cancer. Oncotarget. PMID 26840454 DOI: 10.18632/Oncotarget.7047 |
0.414 |
|
| 2016 |
Liu Z, Beach JA, Agadjanian H, Jia D, Aspuria P, Karlan BY, Orsulic S. Abstract B64: Suboptimal cytoreduction in ovarian carcinoma is associated with molecular pathways characteristic of increased stromal activation. Clinical Cancer Research. 22. DOI: 10.1158/1557-3265.Ovca15-B64 |
0.784 |
|
| 2015 |
Cheon DJ, Walts AE, Beach JA, Lester J, Bomalaski JS, Walsh CS, Ruprecht Wiedemeyer W, Karlan BY, Orsulic S. Differential expression of argininosuccinate synthetase in serous and non-serous ovarian carcinomas. The Journal of Pathology. Clinical Research. 1: 41-53. PMID 27499892 DOI: 10.1002/cjp2.4 |
0.427 |
|
| 2015 |
Jim HS, Lin HY, Tyrer JP, Lawrenson K, Dennis J, Chornokur G, Chen Z, Chen AY, Permuth-Wey J, Aben KK, Anton-Culver H, Antonenkova N, Bruinsma F, Bandera EV, Bean YT, ... ... Orsulic S, et al. Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). Journal of Genetics and Genome Research. 2. PMID 26807442 |
0.435 |
|
| 2015 |
Beach JA, Aspuria PP, Cheon DJ, Lawrenson K, Agadjanian H, Walsh CS, Karlan BY, Orsulic S. Sphingosine kinase 1 is required for TGF-β mediated fibroblastto- myofibroblast differentiation in ovarian cancer. Oncotarget. PMID 26716409 DOI: 10.18632/Oncotarget.6703 |
0.58 |
|
| 2015 |
Amankwah EK, Lin HY, Tyrer JP, Lawrenson K, Dennis J, Chornokur G, Aben KK, Anton-Culver H, Antonenkova N, Bruinsma F, Bandera EV, Bean YT, Beckmann MW, Bisogna M, Bjorge L, ... ... Orsulic S, et al. Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. Genetic Epidemiology. PMID 26399219 DOI: 10.1002/Gepi.21921 |
0.401 |
|
| 2015 |
Lawrenson K, Li Q, Kar S, Seo JH, Tyrer J, Spindler TJ, Lee J, Chen Y, Karst A, Drapkin R, Aben KK, Anton-Culver H, Antonenkova N, Baker H, ... ... Orsulic S, et al. Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. Nature Communications. 6: 8234. PMID 26391404 DOI: 10.1038/Ncomms9234 |
0.422 |
|
| 2015 |
Liu Z, Beach JA, Agadjanian H, Jia D, Aspuria PJ, Karlan BY, Orsulic S. Suboptimal cytoreduction in ovarian carcinoma is associated with molecular pathways characteristic of increased stromal activation. Gynecologic Oncology. PMID 26348314 DOI: 10.1097/Ogx.0000000000000320 |
0.762 |
|
| 2015 |
Kar SP, Tyrer JP, Li Q, Lawrenson K, Aben KK, Anton-Culver H, Antonenkova N, Chenevix-Trench G, Baker H, Bandera E, Bean YT, Beckmann MW, Berchuck A, Bisogna M, Bjørge L, ... ... Orsulic S, et al. Network-based integration of GWAS and gene expression identifies a HOX-centric network associated with serous ovarian cancer risk. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 26209509 DOI: 10.1158/1055-9965.Epi-14-1270 |
0.444 |
|
| 2015 |
Johnatty S, Tyrer JP, Kar SP, Beesley J, Lu Y, Gao B, Fasching PA, Hein A, Ekici AB, Beckmann MW, Lambrechts D, Van Nieuwenhuysen E, Vergote I, Lambrechts S, Rossing MA, ... ... Orsulic S, et al. Genome-wide analysis identifies novel loci associated with ovarian cancer outcomes: findings from the Ovarian Cancer Association Consortium. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26152742 DOI: 10.1158/1078-0432.Ccr-15-0632 |
0.523 |
|
| 2015 |
Chornokur G, Lin HY, Tyrer JP, Lawrenson K, Dennis J, Amankwah EK, Qu X, Tsai YY, Jim HS, Chen Z, Chen AY, Permuth-Wey J, Aben KKh, Anton-Culver H, Antonenkova N, ... ... Orsulic S, et al. Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. Plos One. 10: e0128106. PMID 26091520 DOI: 10.1371/Journal.Pone.0128106 |
0.471 |
|
| 2015 |
Wang L, Amoozgar Z, Huang J, Saleh MH, Xing D, Orsulic S, Goldberg MS. Decitabine enhances lymphocyte migration and function and synergizes with CTLA-4 blockade in a murine ovarian cancer model. Cancer Immunology Research. PMID 26056145 DOI: 10.1158/2326-6066.Cir-15-0073 |
0.563 |
|
| 2015 |
Huang J, Wang L, Cong Z, Amoozgar Z, Kiner E, Xing D, Orsulic S, Matulonis U, Goldberg MS. The PARP1 inhibitor BMN 673 exhibits immunoregulatory effects in a Brca1(-/-) murine model of ovarian cancer. Biochemical and Biophysical Research Communications. 463: 551-6. PMID 26047697 DOI: 10.1016/J.Bbrc.2015.05.083 |
0.614 |
|
| 2015 |
Hollestelle A, van der Baan FH, Berchuck A, Johnatty SE, Aben KK, Agnarsson BA, Aittomäki K, Alducci E, Andrulis IL, Anton-Culver H, Antonenkova NN, Antoniou AC, Apicella C, Arndt V, ... ... Orsulic S, et al. No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology. PMID 25940428 DOI: 10.1016/J.Ygyno.2015.04.034 |
0.431 |
|
| 2015 |
Cheon DJ, Li AJ, Beach JA, Walts AE, Tran H, Lester J, Karlan BY, Orsulic S. ADAM12 is a prognostic factor associated with an aggressive molecular subtype of high-grade serous ovarian carcinoma. Carcinogenesis. PMID 25926422 DOI: 10.1093/Carcin/Bgv059 |
0.565 |
|
| 2015 |
Blein S, Bardel C, Danjean V, McGuffog L, Healey S, Barrowdale D, Lee A, Dennis J, Kuchenbaecker KB, Soucy P, Terry MB, Chung WK, Goldgar DE, Buys SS, ... ... Orsulic S, et al. An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast Cancer Research : Bcr. 17: 61. PMID 25925750 DOI: 10.1186/S13058-015-0567-2 |
0.353 |
|
| 2015 |
Lojkin I, Rubinek T, Orsulic S, Schwarzmann O, Karlan BY, Bose S, Wolf I. Reduced expression and growth inhibitory activity of the aging suppressor klotho in epithelial ovarian cancer. Cancer Letters. 362: 149-57. PMID 25827069 DOI: 10.1016/J.Canlet.2015.03.035 |
0.541 |
|
| 2015 |
Taylor-Harding B, Aspuria PJ, Agadjanian H, Cheon DJ, Mizuno T, Greenberg D, Allen JR, Spurka L, Funari V, Spiteri E, Wang Q, Orsulic S, Walsh C, Karlan BY, Wiedemeyer WR. Cyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS. Oncotarget. 6: 696-714. PMID 25557169 DOI: 10.18632/Oncotarget.2673 |
0.481 |
|
| 2015 |
Walts AE, Bomalaski JS, Ines D, Orsulic S. Argininosuccinate synthetase (ASS) deficiency in high-grade pulmonary neuroendocrine carcinoma: an opportunity for personalized targeted therapy. Journal of Cancer Research and Clinical Oncology. 141: 1363-9. PMID 25548129 DOI: 10.1007/S00432-014-1904-Z |
0.405 |
|
| 2015 |
Lee AW, Tyrer JP, Doherty JA, Stram DA, Kupryjanczyk J, Dansonka-Mieszkowska A, Plisiecka-Halasa J, Spiewankiewicz B, Myers EJ, Chenevix-Trench G, Fasching PA, Beckmann MW, Ekici AB, ... ... Orsulic S, et al. Evaluating the ovarian cancer gonadotropin hypothesis: a candidate gene study. Gynecologic Oncology. 136: 542-8. PMID 25528498 DOI: 10.1016/J.Ygyno.2014.12.017 |
0.471 |
|
| 2015 |
Peterlongo P, Chang-Claude J, Moysich KB, Rudolph A, Schmutzler RK, Simard J, Soucy P, Eeles RA, Easton DF, Hamann U, Wilkening S, Chen B, Rookus MA, Schmidt MK, van der Baan FH, ... ... Orsulic S, et al. Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 24: 308-16. PMID 25336561 DOI: 10.1158/1055-9965.Epi-14-0532 |
0.404 |
|
| 2015 |
Walsh C, Nassanian H, Agadjanian H, Miller C, Orsulic S, Karlan B. Abstract POSTER-BIOL-1348: No association between PARK2 and BRCA1-associated gynecologic cancers Clinical Cancer Research. 21. DOI: 10.1158/1557-3265.Ovcasymp14-Poster-Biol-1348 |
0.522 |
|
| 2015 |
Beach JA, Aspuria P, Cheon D, Gozo MC, Karlan BY, Orsulic S. Abstract B09: Sphingosine kinase 1 (SPHK1) is a novel mediator of tumor-stroma interaction in ovarian cancer Cancer Research. 75. DOI: 10.1158/1538-7445.Chtme14-B09 |
0.842 |
|
| 2015 |
Cheon D, Beach J, Walts A, Karlan B, Orsulic S. Abstract A39: COL11A1 is a regulator of tumor microenvironment and a biomarker of metastatic progression Cancer Research. 75. DOI: 10.1158/1538-7445.Chtme14-A39 |
0.846 |
|
| 2014 |
Aspuria PJ, Lunt SY, Väremo L, Vergnes L, Gozo M, Beach JA, Salumbides B, Reue K, Wiedemeyer WR, Nielsen J, Karlan BY, Orsulic S. Succinate dehydrogenase inhibition leads to epithelial-mesenchymal transition and reprogrammed carbon metabolism. Cancer & Metabolism. 2: 21. PMID 25671108 DOI: 10.1186/2049-3002-2-21 |
0.455 |
|
| 2014 |
Jin Y, Han B, Chen J, Wiedemeyer R, Orsulic S, Bose S, Zhang X, Karlan BY, Giuliano AE, Cui Y, Cui X. FOXC1 is a critical mediator of EGFR function in human basal-like breast cancer. Annals of Surgical Oncology. 21: S758-66. PMID 25124473 DOI: 10.1245/S10434-014-3980-3 |
0.429 |
|
| 2014 |
Kelemen LE, Terry KL, Goodman MT, Webb PM, Bandera EV, McGuire V, Rossing MA, Wang Q, Dicks E, Tyrer JP, Song H, Kupryjanczyk J, Dansonka-Mieszkowska A, Plisiecka-Halasa J, Timorek A, ... ... Orsulic S, et al. Consortium analysis of gene and gene-folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk. Molecular Nutrition & Food Research. 58: 2023-35. PMID 25066213 DOI: 10.1002/Mnfr.201400068 |
0.317 |
|
| 2014 |
Hedditch EL, Gao B, Russell AJ, Lu Y, Emmanuel C, Beesley J, Johnatty SE, Chen X, Harnett P, George J, Williams RT, Flemming C, Lambrechts D, Despierre E, ... ... Orsulic S, et al. ABCA transporter gene expression and poor outcome in epithelial ovarian cancer. Journal of the National Cancer Institute. 106. PMID 24957074 DOI: 10.1093/Jnci/Dju149 |
0.514 |
|
| 2014 |
Cheon DJ, Orsulic S. Ten-gene biomarker panel: a new hope for ovarian cancer? Biomarkers in Medicine. 8: 523-6. PMID 24796616 DOI: 10.2217/Bmm.14.16 |
0.53 |
|
| 2014 |
Mantia-Smaldone G, Ronner L, Blair A, Gamerman V, Morse C, Orsulic S, Rubin S, Gimotty P, Adams S. The immunomodulatory effects of pegylated liposomal doxorubicin are amplified in BRCA1--deficient ovarian tumors and can be exploited to improve treatment response in a mouse model. Gynecologic Oncology. 133: 584-90. PMID 24680909 DOI: 10.1016/J.Ygyno.2014.03.565 |
0.603 |
|
| 2014 |
Yuan J, Kashiwagi S, Reeves P, Nezivar J, Yang Y, Arrifin NH, Nguyen M, Jean-Mary G, Tong X, Uppal P, Korochkina S, Forbes B, Chen T, Righi E, Bronson R, ... ... Orsulic S, et al. A novel mycobacterial Hsp70-containing fusion protein targeting mesothelin augments antitumor immunity and prolongs survival in murine models of ovarian cancer and mesothelioma. Journal of Hematology & Oncology. 7: 15. PMID 24565018 DOI: 10.1186/1756-8722-7-15 |
0.44 |
|
| 2014 |
Karlan BY, Dering J, Walsh C, Orsulic S, Lester J, Anderson LA, Ginther CL, Fejzo M, Slamon D. POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer. Gynecologic Oncology. 132: 334-42. PMID 24368280 DOI: 10.1016/J.Ygyno.2013.12.021 |
0.556 |
|
| 2014 |
Cheon DJ, Tong Y, Sim MS, Dering J, Berel D, Cui X, Lester J, Beach JA, Tighiouart M, Walts AE, Karlan BY, Orsulic S. A collagen-remodeling gene signature regulated by TGF-β signaling is associated with metastasis and poor survival in serous ovarian cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 711-23. PMID 24218511 DOI: 10.1158/1078-0432.Ccr-13-1256 |
0.584 |
|
| 2014 |
He L, Guo L, Vathipadiekal V, Sergent PA, Growdon WB, Engler DA, Rueda BR, Birrer MJ, Orsulic S, Mohapatra G. Identification of LMX1B as a novel oncogene in human ovarian cancer. Oncogene. 33: 4226-35. PMID 24056967 DOI: 10.1038/Onc.2013.375 |
0.593 |
|
| 2014 |
Taylor-Harding B, Agadjanian H, Aspuria P, Cheon D, Mizuno T, Greenberg D, Allen JR, Orsulic S, Walsh C, Karlan BY, Wiedemeyer WR. Abstract 678: The Ets factor ETV5 regulates E2F target genes and mediates drug resistance Cancer Research. 74: 678-678. DOI: 10.1158/1538-7445.Am2014-678 |
0.821 |
|
| 2014 |
Mohapatra G, He L, Guo L, Vathipadiekal V, Sergent P, Growdon W, Rueda B, Engler D, Orsulic S, Birrer M. Abstract 1534: Identification of LMX1B as a novel oncogene in human ovarian cancer Cancer Research. 74: 1534-1534. DOI: 10.1158/1538-7445.Am2014-1534 |
0.628 |
|
| 2014 |
Li A, Cheon D, Karlan B, Orsulic S. The prognostic significance of ADAM metallopeptidase domain 12 in advanced stage serous ovarian cancer Gynecologic Oncology. 135: 386. DOI: 10.1016/J.Ygyno.2014.07.018 |
0.799 |
|
| 2014 |
Higuchi T, Flies D, Mantia-Smaldone G, Ronner P, Alldredge J, Orsulic S, Adams S. PARP inhibition synergizes with anti-CTLA-4 immune therapy to promote rejection of peritoneal tumors in mouse models of ovarian cancer Gynecologic Oncology. 133: 115-116. DOI: 10.1016/J.Ygyno.2014.03.305 |
0.502 |
|
| 2013 |
Kulkarni-Datar K, Orsulic S, Foster R, Rueda BR. Ovarian tumor initiating cell populations persist following paclitaxel and carboplatin chemotherapy treatment in vivo. Cancer Letters. 339: 237-46. PMID 23791886 DOI: 10.1016/J.Canlet.2013.06.014 |
0.529 |
|
| 2013 |
Couch FJ, Wang X, McGuffog L, Lee A, Olswold C, Kuchenbaecker KB, Soucy P, Fredericksen Z, Barrowdale D, Dennis J, Gaudet MM, Dicks E, Kosel M, Healey S, Sinilnikova OM, ... ... Orsulic S, et al. Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. Plos Genetics. 9: e1003212. PMID 23544013 DOI: 10.1371/Journal.Pgen.1003212 |
0.433 |
|
| 2013 |
Jin Y, Han B, Wiedemeyer WR, Orsulic S, Karlan B, Giuliano A, Cui X. Abstract 5443: FOXC1 is a critical mediator of EGFR function in basal-like breast cancer. Cancer Research. 73: 5443-5443. DOI: 10.1158/1538-7445.Am2013-5443 |
0.401 |
|
| 2013 |
Agadjanian H, Cheon D, Diaz E, Laury A, Miller C, Karlan B, Orsulic S, Walsh C. Abstract 329: A mouse model of epithelial ovarian cancer with defined oncogenic drivers. Cancer Research. 73: 329-329. DOI: 10.1158/1538-7445.Am2013-329 |
0.811 |
|
| 2013 |
Taylor-Harding B, Agadjanian H, Orsulic S, Walsh C, Karlan BY, Wiedemeyer W. Abstract 1749: Cell cycle requirements shape ovarian cancer progression. Cancer Research. 73: 1749-1749. DOI: 10.1158/1538-7445.Am2013-1749 |
0.633 |
|
| 2013 |
Cheon D, Tong Y, Sim M, Cui X, Berel D, Tighiouart M, Wiedemeyer WR, Karlan B, Orsulic S. Abstract 1511: Stromal gene signature regulated by TGFβ signaling predicts poor clinical outcome in ovarian cancer . Cancer Research. 73: 1511-1511. DOI: 10.1158/1538-7445.Am2013-1511 |
0.835 |
|
| 2013 |
Aspuria P, Cheon D, Gozo M, Salumbides B, Vergnes L, Asara J, Reue K, Kensicki E, Karlan B, Orsulic S. Abstract 1088: HOXB13 inhibition of succinate dehydrogenase leads to epithelial-to-mesenchymal transition in mouse ovarian cancer cell lines. Cancer Research. 73: 1088-1088. DOI: 10.1158/1538-7445.Am2013-1088 |
0.839 |
|
| 2013 |
Cheon D, Beach J, Tong Y, Cui X, Tighiouart M, Liu Z, Walts AE, Karlan BY, Orsulic S. Abstract IA11: Using publicly available databases for the functional characterization of cancer genes Clinical Cancer Research. 19. DOI: 10.1158/1078-0432.Ovca13-Ia11 |
0.849 |
|
| 2013 |
Taylor-Harding B, Agadjanian H, Aspuria PJ, Mizuno T, Cheon D, Orsulic S, Karlan B, Walsh C, Wiedemeyer WR. Abstract B48: Targeting chemo-resistance in CCNE1-amplified ovarian cancer Clinical Cancer Research. 19. DOI: 10.1158/1078-0432.Ovca13-B48 |
0.84 |
|
| 2013 |
Diaz E, Agadjanian H, Nassanian H, Walts A, Miller C, Zajchowski D, Karlan B, Orsulic S, Walsh C. PI3K pathway activation, thromboembolism and survival in ovarian clear cell carcinoma Gynecologic Oncology. 130: e128. DOI: 10.1016/J.Ygyno.2013.04.367 |
0.387 |
|
| 2012 |
Engler DA, Gupta S, Growdon WB, Drapkin RI, Nitta M, Sergent PA, Allred SF, Gross J, Deavers MT, Kuo WL, Karlan BY, Rueda BR, Orsulic S, Gershenson DM, Birrer MJ, et al. Genome wide DNA copy number analysis of serous type ovarian carcinomas identifies genetic markers predictive of clinical outcome. Plos One. 7: e30996. PMID 22355333 DOI: 10.1371/Journal.Pone.0030996 |
0.444 |
|
| 2012 |
Taylor-Harding B, Agadjanian H, Nassanian H, Kwon S, Guo X, Miller C, Karlan BY, Orsulic S, Walsh CS. Indole-3-carbinol synergistically sensitises ovarian cancer cells to bortezomib treatment. British Journal of Cancer. 106: 333-43. PMID 22166800 DOI: 10.1038/Bjc.2011.546 |
0.487 |
|
| 2012 |
Fleming ND, Agadjanian H, Nassanian H, Miller CW, Orsulic S, Karlan BY, Walsh CS. Xeroderma pigmentosum complementation group C single-nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression-free survival in advanced ovarian cancer. Cancer. 118: 689-97. PMID 21751198 DOI: 10.1002/Cncr.26329 |
0.379 |
|
| 2012 |
Kulkarni-Datar KS, Orsulic S, Foster R, Rueda BR. Abstract 3474: Ovarian cancer tumor initiating cells persist after paclitaxel and carboplatinum treatmentin vivo Cancer Research. 72: 3474-3474. DOI: 10.1158/1538-7445.Am2012-3474 |
0.523 |
|
| 2012 |
Yuan J, Leblanc P, Kashiwagi S, Nezivar J, Righi E, Santosuosso M, Korochkina S, Orsulic S, Scholler N, Dranoff G, Gelfand J, Poznansky M. Abstract 1578: MTBhsp70 fusion protein targeting mesothelin augments tumor specific T cell responses and prolongs survival in a murine model of ovarian cancer Cancer Research. 72: 1578-1578. DOI: 10.1158/1538-7445.Am2012-1578 |
0.425 |
|
| 2012 |
Diaz E, Fleming N, Nassanian H, Walts A, Zajchowski D, Orsulic S, Walsh C. PI3K pathway activation and thromboembolism in ovarian clear cell carcinomas Gynecologic Oncology. 127: S1-S2. DOI: 10.1016/J.Ygyno.2012.07.005 |
0.386 |
|
| 2012 |
Mantia-Smaldone G, Gamerman V, Gimotty P, Loomis R, Orsulic S, Rubin S, Coukos G, Adams S. CD8 T cell-mediated immune responses are critical to the increased efficacy of Doxil in BRCA1 deficient tumors Gynecologic Oncology. 125: S37-S38. DOI: 10.1016/J.Ygyno.2011.12.085 |
0.326 |
|
| 2012 |
Li Y, Ferris A, Lewis BC, Orsulic S, Williams BO, Holland EC, Hughes SH. The RCAS/TVA somatic gene transfer method in modeling human cancer Genetically Engineered Mice For Cancer Research: Design, Analysis, Pathways, Validation and Pre-Clinical Testing. 83-111. DOI: 10.1007/978-0-387-69805-2_5 |
0.706 |
|
| 2012 |
Fleming N, Agadjanian H, Nassanian H, Miller CW, Orsulic S, Karlan BY, Walsh CS. Erratum: Xeroderma pigmentosum complementation group C single-nucleotide polymorphisms in the nucleotide excision repair pathway correlate with prolonged progression-free survival in advanced ovarian cancer (Cancer. 118 DOI: 10.1002/cncr.27557 (2012) (689-697)) Cancer. 118. DOI: 10.1002/Cncr.27557 |
0.489 |
|
| 2011 |
Righi E, Kashiwagi S, Yuan J, Santosuosso M, Leblanc P, Ingraham R, Forbes B, Edelblute B, Collette B, Xing D, Kowalski M, Mingari MC, Vianello F, Birrer M, Orsulic S, et al. CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer. Cancer Research. 71: 5522-34. PMID 21742774 DOI: 10.1158/0008-5472.Can-10-3143 |
0.616 |
|
| 2011 |
Bell D, Berchuck A, Birrer M, Chien J, Cramer DW, Dao F, Dhir R, Disaia P, Gabra H, Glenn P, Godwin AK, Gross J, Hartmann L, Huang M, Huntsman DG, ... ... Orsulic S, et al. Integrated genomic analyses of ovarian carcinoma Nature. 474: 609-615. PMID 21720365 DOI: 10.1038/Nature10166 |
0.532 |
|
| 2011 |
Goldberg MS, Xing D, Ren Y, Orsulic S, Bhatia SN, Sharp PA. Nanoparticle-mediated delivery of siRNA targeting Parp1 extends survival of mice bearing tumors derived from Brca1-deficient ovarian cancer cells. Proceedings of the National Academy of Sciences of the United States of America. 108: 745-50. PMID 21187397 DOI: 10.1073/Pnas.1016538108 |
0.599 |
|
| 2011 |
Cheon DJ, Orsulic S. Mouse models of cancer. Annual Review of Pathology. 6: 95-119. PMID 20936938 DOI: 10.1146/Annurev.Pathol.3.121806.154244 |
0.533 |
|
| 2011 |
Kashiwagi S, Righi E, Yuan J, Santosuosso M, Ingraham R, Orsulic S, Birrer M, Penson R, Dranoff G, Poznansky MC. Abstract LB-387: Blockade of the CXCL12/CXCR4 axis with AMD3100 induces multimodal antitumor effects in murine ovarian cancer and prolongs survival Cancer Research. 71. DOI: 10.1158/1538-7445.Am2011-Lb-387 |
0.646 |
|
| 2011 |
Mantia-Smaldone G, Marsh E, Loomis R, Orsulic S, Rubin S, Coukos G, Adams S. BRCA1-deficient tumors demonstrate enhanced cytotoxicity and T-cell recruitment following doxil treatment Gynecologic Oncology. 120: S22. DOI: 10.1016/J.Ygyno.2010.12.056 |
0.382 |
|
| 2011 |
Fleming N, Agadjanian H, Miller C, Orsulic S, Karlan B, Walsh C. XPC single-nucleotide polymorphisms correlate with prolonged progression-free survival in advanced ovarian cancer Gynecologic Oncology. 120. DOI: 10.1016/J.Ygyno.2010.12.020 |
0.456 |
|
| 2010 |
Hall CA, Wang R, Miao J, Oliva E, Shen X, Wheeler T, Hilsenbeck SG, Orsulic S, Goode S. Hippo pathway effector Yap is an ovarian cancer oncogene. Cancer Research. 70: 8517-25. PMID 20947521 DOI: 10.1158/0008-5472.Can-10-1242 |
0.596 |
|
| 2010 |
Taylor-Harding B, Orsulic S, Karlan BY, Li AJ. Fluvastatin and cisplatin demonstrate synergistic cytotoxicity in epithelial ovarian cancer cells. Gynecologic Oncology. 119: 549-56. PMID 20837358 DOI: 10.1016/J.Ygyno.2010.08.017 |
0.602 |
|
| 2010 |
Ibrahim N, He L, Leong CO, Xing D, Karlan BY, Swisher EM, Rueda BR, Orsulic S, Ellisen LW. BRCA1-associated epigenetic regulation of p73 mediates an effector pathway for chemosensitivity in ovarian carcinoma. Cancer Research. 70: 7155-65. PMID 20807817 DOI: 10.1158/0008-5472.Can-10-0668 |
0.51 |
|
| 2010 |
Singavarapu R, Buchinsky N, Cheon DJ, Orsulic S. Whole ovary immunohistochemistry for monitoring cell proliferation and ovulatory wound repair in the mouse. Reproductive Biology and Endocrinology : Rb&E. 8: 98. PMID 20712898 DOI: 10.1186/1477-7827-8-98 |
0.403 |
|
| 2010 |
Deng S, Yang X, Lassus H, Liang S, Kaur S, Ye Q, Li C, Wang LP, Roby KF, Orsulic S, Connolly DC, Zhang Y, Montone K, Bützow R, Coukos G, et al. Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers. Plos One. 5: e10277. PMID 20422001 DOI: 10.1371/Journal.Pone.0010277 |
0.631 |
|
| 2010 |
Taylor-Harding B, Orsulic S, Miller C, Berenson JR, Karlan B, Walsh C. Abstract 3880: The natural dietary phytochemical indole-3-carbinole (I3C) sensitizes ovarian cancer cells to the proteasome inhibitor bortezomib through inhibition of cyclin E activity Cancer Research. 70: 3880-3880. DOI: 10.1158/1538-7445.Am10-3880 |
0.489 |
|
| 2010 |
Ioffe Y, Xuan X, Gayatry M, Deyin X, Oliva E, Karlan B, Orsulic S. BRCA1 expression is downregulated in uterine leiomyosarcomas Gynecologic Oncology. 116: 596-597. DOI: 10.1016/J.Ygyno.2009.10.022 |
0.315 |
|
| 2009 |
Xing D, Scangas G, Nitta M, He L, Xu X, Ioffe YJ, Aspuria PJ, Hedvat CY, Anderson ML, Oliva E, Karlan BY, Mohapatra G, Orsulic S. A role for BRCA1 in uterine leiomyosarcoma. Cancer Research. 69: 8231-5. PMID 19843854 DOI: 10.1158/0008-5472.Can-09-2543 |
0.429 |
|
| 2008 |
Miao J, Mu D, Ergel B, Singavarapu R, Duan Z, Powers S, Oliva E, Orsulic S. Hepsin colocalizes with desmosomes and induces progression of ovarian cancer in a mouse model. International Journal of Cancer. 123: 2041-7. PMID 18726901 DOI: 10.1002/Ijc.23726 |
0.619 |
|
| 2008 |
Wang Y, Cheon DJ, Lu Z, Cunningham SL, Chen CM, Luo RZ, Xing D, Orsulic S, Bast RC, Behringer RR. MUC16 expression during embryogenesis, in adult tissues, and ovarian cancer in the mouse. Differentiation; Research in Biological Diversity. 76: 1081-92. PMID 18637025 DOI: 10.1111/J.1432-0436.2008.00295.X |
0.622 |
|
| 2008 |
Sakamoto H, Friel AM, Wood AW, Guo L, Ilic A, Seiden MV, Chung DC, Lynch MP, Serikawa T, Munro E, Oliva E, Orsulic S, Kirley SD, Foster R, Zukerberg LR, et al. Mechanisms of Cables 1 gene inactivation in human ovarian cancer development. Cancer Biology & Therapy. 7: 180-88. PMID 18059193 DOI: 10.4161/Cbt.7.2.5253 |
0.479 |
|
| 2007 |
Miao J, Wang Z, Provencher H, Muir B, Dahiya S, Carney E, Leong CO, Sgroi DC, Orsulic S. HOXB13 promotes ovarian cancer progression. Proceedings of the National Academy of Sciences of the United States of America. 104: 17093-8. PMID 17942676 DOI: 10.1073/Pnas.0707938104 |
0.633 |
|
| 2007 |
Daikoku T, Tranguch S, Chakrabarty A, Wang D, Khabele D, Orsulic S, Morrow JD, Dubois RN, Dey SK. Extracellular signal-regulated kinase is a target of cyclooxygenase-1-peroxisome proliferator-activated receptor-delta signaling in epithelial ovarian cancer. Cancer Research. 67: 5285-92. PMID 17545608 DOI: 10.1158/0008-5472.Can-07-0828 |
0.441 |
|
| 2007 |
Chaudhuri D, Orsulic S, Ashok BT. Antiproliferative activity of sulforaphane in Akt-overexpressing ovarian cancer cells. Molecular Cancer Therapeutics. 6: 334-45. PMID 17237292 DOI: 10.1158/1535-7163.Mct-06-0404 |
0.551 |
|
| 2006 |
Sale S, Orsulic S. Models of ovarian cancer metastasis: Murine models. Drug Discovery Today. Disease Models. 3: 149-154. PMID 19337569 DOI: 10.1016/J.Ddmod.2006.05.006 |
0.583 |
|
| 2006 |
Xing D, Orsulic S. A mouse model for the molecular characterization of Brca1-associated ovarian carcinoma Cancer Research. 66: 8949-8953. PMID 16982732 DOI: 10.1158/0008-5472.Can-06-1495 |
0.578 |
|
| 2005 |
Gasser S, Orsulic S, Brown EJ, Raulet DH. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature. 436: 1186-90. PMID 15995699 DOI: 10.1038/Nature03884 |
0.336 |
|
| 2005 |
Xing D, Orsulic S. Modeling resistance to pathway-targeted therapy in ovarian cancer Cell Cycle. 4: 1004-1006. PMID 15970711 DOI: 10.4161/Cc.4.8.1869 |
0.571 |
|
| 2005 |
Daikoku T, Wang D, Tranguch S, Morrow JD, Orsulic S, DuBois RN, Dey SK. Cyclooxygenase-1 is a potential target for prevention and treatment of ovarian epithelial cancer. Cancer Research. 65: 3735-44. PMID 15867369 DOI: 10.1158/0008-5472.Can-04-3814 |
0.618 |
|
| 2005 |
Xing D, Orsulic S. A genetically defined mouse ovarian carcinoma model for the molecular characterization of pathway-targeted therapy and tumor resistance Proceedings of the National Academy of Sciences of the United States of America. 102: 6936-6941. PMID 15860581 DOI: 10.1073/Pnas.0502256102 |
0.47 |
|
| 2004 |
Balkwill F, Bast R, Berek J, Chenevix-Trench G, Gore M, Hamilton T, Jacobs I, Mills G, Souhami R, Urban N, Orsulic S, Smyth J. Erratum to “Current research and treatment for epithelial ovarian cancer. A Position Paper from the Helene Harris Memorial Trust” [European Journal of Cancer, 39 (2003) 1818–1827] European Journal of Cancer. 40: 628. DOI: 10.1016/J.Ejca.2003.11.005 |
0.375 |
|
| 2002 |
Orsulic S, Li Y, Soslow RA, Vitale-Cross LA, Gutkind JS, Varmus HE. Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. Cancer Cell. 1: 53-62. PMID 12086888 DOI: 10.1016/S1535-6108(01)00002-2 |
0.671 |
|
| 1999 |
Fisher GH, Orsulic S, Holland E, Hively WP, Li Y, Lewis BC, Williams BO, Varmus HE. Development of a flexible and specific gene delivery system for production of murine tumor models. Oncogene. 18: 5253-60. PMID 10498877 DOI: 10.1038/Sj.Onc.1203087 |
0.759 |
|
| 1996 |
Orsulic S, Peifer M. Cell-cell signalling: Wingless lands at last Current Biology. 6: 1363-1367. PMID 8939593 DOI: 10.1016/S0960-9822(96)00731-2 |
0.554 |
|
| 1996 |
Orsulic S, Peifer M. An in vivo structure-function study of Armadillo, the β-catenin homologue, reveals both separate and overlapping regions of the protein required for cell adhesion and for wingless signaling Journal of Cell Biology. 134: 1283-1300. PMID 8794868 DOI: 10.1083/Jcb.134.5.1283 |
0.524 |
|
| Show low-probability matches. |